A1 Refereed original research article in a scientific journal
ISOLATION AND CHARACTERIZATION OF ACLACINOMYCIN-A-NON-PRODUCING STREPTOMYCES-GALILAEUS (ATCC-31615) MUTANTS
Authors: YLIHONKO K, HAKALA J, NIEMI J, LUNDELL J, MANTSALA P
Publisher: SOC GENERAL MICROBIOLOGY
Publication year: 1994
Journal:: Microbiology
Journal name in source: MICROBIOLOGY-UK
Journal acronym: MICROBIOL-UK
Volume: 140
First page : 1359
Last page: 1365
Number of pages: 7
ISSN: 1350-0872
DOI: https://doi.org/10.1099/00221287-140-6-1359
Abstract
Twelve mutants of Streptomyces galilaeus (ATCC 31615) blocked in the production of aclacinomycin A, an anthracycline antibiotic with significant antitumour activity, accumulated intermediates of the biosynthesis of aclacinomycins and several anthracyclines with variant sugar moieties. Three of these aklavinone glycosides have not been described before. Mutant strains H028, H061 and H036 were blocked before the formation of aklavinone, a common intermediate for most anthracyclines. Strain H039 accumulated aklavinone and H026, H035, H038 and H054 had mutations that changed glycosylation of aklavinone. Characterization of the mutants and their products is described.
Twelve mutants of Streptomyces galilaeus (ATCC 31615) blocked in the production of aclacinomycin A, an anthracycline antibiotic with significant antitumour activity, accumulated intermediates of the biosynthesis of aclacinomycins and several anthracyclines with variant sugar moieties. Three of these aklavinone glycosides have not been described before. Mutant strains H028, H061 and H036 were blocked before the formation of aklavinone, a common intermediate for most anthracyclines. Strain H039 accumulated aklavinone and H026, H035, H038 and H054 had mutations that changed glycosylation of aklavinone. Characterization of the mutants and their products is described.
UTU Research Portal